"The fact that the median PFS on active therapy was no better at all than the median on placebo appears to be the kind of anomaly I was talking about earlier"
Mr. Keane did agree with these thoughts which is why he went on to give me the prior mentioned examples. It was also discussed with the FDA when designing the 2nd phase 3 trial.
He did note that besides the prior erbitux, taxol, and traveca examples, the fact that the duration of response was much longer and the OS was much longer, should remove some, not all of these concerns.
Randy
Market Data 
Markets 
AI
